Use of the subcutaneous route for the administration of narcotics in patients with cancer pain.
From February 1985 until January 1987, 108 consecutive patients with pain due to advanced cancer requiring parenteral narcotics were treated with a subcutaneous infusion of morphine (62 patients) or hydromorphone (46 patients). Mean maximal daily dose of morphine and hydromorphone was 305 mg (range, 80-3000 mg) and 310 mg (range, 40-4024 mg), respectively. The infusion was maintained for a mean of 31 +/- 16 days (range, 2-156). Seventy patients were treated with a portable pump. Of these patients, 33 (45%) were discharge home for a mean of 29 +/- 20 days. Eighty-six of one hundred eight (86/108, 80%) patients experienced adequate pain control (less than two extra doses of analgesics per day). The duration of the site of the infusion was 7 days (range, 2-31). The mean daily increase in those was 2.4 +/- 1.6% of the initial dose (only 15% of patients needed an increase more than or equal to 5% per day). Systemic toxicity consisted of respiratory depression in two patients, severe sedation in six, and confusion in three; all patients improved upon reduction of the daily dose of narcotics. Local toxicity consisted in infection in two patients, bleeding in one, and chemical irritation in six. Cost analysis shows that subcutaneous infusion reduced costs by either allowing home discharges, or replacing intravenous infusion. The authors conclude that this method is safe and effective in patients admitted and at home, and should be considered the first choice when parenteral analgesia is required.
Bruera
E
E
Department of Medicine, Cross Cancer Institute, Edmonton, Alberta.
Brenneis
C
C
Michaud
M
M
Bacovsky
R
R
Chadwick
S
S
Emeno
A
A
MacDonald
N
N
D003362:Cost-Benefit Analysis; D005260:Female; D006699:Home Care Services; D006801:Humans; D004091:Hydromorphone / Q000008:administration & dosage*; D007260:Infusion Pumps; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D009020:Morphine / Q000008:administration & dosage*; D009369:Neoplasms / Q000188:drug therapy*; D010148:Intractable Pain / Q000188:drug therapy*
D009020:Morphine; D004091:Hydromorphone